Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-27, Stock:LLY, The news for the past five days is as follows:
2019-06-20: NEWS1: 3 Drugs Under FDA Review With Blockbuster Potential.NEWS2: 3 Drugs Under FDA Review With Blockbuster Potential.NEWS3: Allergan Up As Analyst Statement Sparks Business Split Rumors.NEWS4: Allergan Up As Analyst Statement Sparks Business Split Rumors.NEWS5: Opinion: Medical Marijuana Is a Terrible Investment.NEWS6: Opinion: Medical Marijuana Is a Terrible Investment.NEWS7: Implied EPS Analyst Target Price: $36.NEWS8: Implied EPS Analyst Target Price: $36.
2019-06-21: nan
2019-06-24: NEWS1: Why These Innovative Biotech ETFs Soaring.NEWS2: Why These Innovative Biotech ETFs Soaring.NEWS3: Why These Innovative Biotech ETFs Soaring.NEWS4: Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids.NEWS5: Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids.NEWS6: Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids.
2019-06-25: NEWS1: Axsome Initiates Phase III Study on Depression Candidate.NEWS2: Axsome Initiates Phase III Study on Depression Candidate.NEWS3: Axsome Initiates Phase III Study on Depression Candidate.NEWS4: Allergan acquisition is ‘a major bailout’ for shareholders, according to analysts.NEWS5: Double Top Spells Trouble for 3 Health Care Stocks.NEWS6: The 10 Biggest Biotech Stocks.NEWS7: Allergan Up As Analyst Statement Sparks Business Split Rumors.
2019-06-26: NEWS1: Wednesday Sector Laggards: Utilities, Healthcare.NEWS2: Wednesday Sector Laggards: Utilities, Healthcare.NEWS3: Lilly's Heart Drug Snags Fast Track Designation; Type 2 Diabetes Drug Found Effective At Higher Doses.NEWS4: The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart.NEWS5: Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes.NEWS6: U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure.

Answer: Rise